1 |
DRD1
| [10] Calcium signaling pathway Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Amphetamine addiction, Morphine addiction, Alcoholism | D00633
D00633
|
Dopamine
| [4] 6 6, 7, 74, 299 |
2 |
DRD1
| [10] Calcium signaling pathway Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Amphetamine addiction, Morphine addiction, Alcoholism | D07870
D07870
|
Dopamine
| [4] 6 6, 7, 74, 299 |
3 |
DRD2
| [8] Rap1 signaling pathway Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Alcoholism | D00633
D00633
|
Dopamine
| [4] 6 6, 7, 74, 299 |
4 |
DRD2
| [8] Rap1 signaling pathway Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Alcoholism | D00780
D00780
|
Bromocriptine
| [2] 6 6, 74 |
5 |
DRD2
| [8] Rap1 signaling pathway Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Alcoholism | D00784
D00784
|
Ropinirole
| [4] 2 2, 6, 74, 309 |
6 |
DRD2
| [8] Rap1 signaling pathway Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Alcoholism | D00987
D00987
|
Cabergoline
| [3] 6 6, 74, 75 |
7 |
DRD2
| [8] Rap1 signaling pathway Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Alcoholism | D03165
D03165
|
Bromocriptine
| [2] 6 6, 74 |
8 |
DRD2
| [8] Rap1 signaling pathway Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Alcoholism | D07870
D07870
|
Dopamine
| [4] 6 6, 7, 74, 299 |
9 |
DRD2
| [8] Rap1 signaling pathway Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Alcoholism | D08489
D08489
|
Ropinirole
| [4] 2 2, 6, 74, 309 |
10 |
DRD3
| [2] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Dopaminergic synapse | D00633
D00633
|
Dopamine
| [4] 6 6, 7, 74, 299 |
11 |
DRD3
| [2] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Dopaminergic synapse | D00784
D00784
|
Ropinirole
| [4] 2 2, 6, 74, 309 |
12 |
DRD3
| [2] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Dopaminergic synapse | D07870
D07870
|
Dopamine
| [4] 6 6, 7, 74, 299 |
13 |
DRD3
| [2] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Dopaminergic synapse | D08489
D08489
|
Ropinirole
| [4] 2 2, 6, 74, 309 |
14 |
DRD4
| [2] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Dopaminergic synapse | D00633
D00633
|
Dopamine
| [4] 6 6, 7, 74, 299 |
15 |
DRD4
| [2] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Dopaminergic synapse | D00784
D00784
|
Ropinirole
| [4] 2 2, 6, 74, 309 |
16 |
DRD4
| [2] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Dopaminergic synapse | D07870
D07870
|
Dopamine
| [4] 6 6, 7, 74, 299 |
17 |
DRD4
| [2] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Dopaminergic synapse | D08489
D08489
|
Ropinirole
| [4] 2 2, 6, 74, 309 |
18 |
DRD5
| [4] Calcium signaling pathway Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Dopaminergic synapse | D00633
D00633
|
Dopamine
| [4] 6 6, 7, 74, 299 |
19 |
DRD5
| [4] Calcium signaling pathway Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Dopaminergic synapse | D07870
D07870
|
Dopamine
| [4] 6 6, 7, 74, 299 |
20 |
EGFR
| [48] EGFR tyrosine kinase inhibitor resistance EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, MAPK signaling pathway, ErbB signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, HIF-1 signaling pathway, FoxO signaling pathway, Phospholipase D signaling pathway, Endocytosis, PI3K-Akt signaling pathway, Focal adhesion, Adherens junction, Gap junction, JAK-STAT signaling pathway, Regulation of actin cytoskeleton, GnRH signaling pathway, Estrogen signaling pathway, Oxytocin signaling pathway, Relaxin signaling pathway, Parathyroid hormone synthesis, secretion and action, Cushing syndrome, Epithelial cell signaling in Helicobacter pylori infection, Shigellosis, Hepatitis C, Human cytomegalovirus infection, Human papillomavirus infection, Coronavirus disease - COVID-19, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Chemical carcinogenesis - receptor activation, Chemical carcinogenesis - reactive oxygen species, Colorectal cancer, Pancreatic cancer, Endometrial cancer, Glioma, Prostate cancer, Melanoma, Bladder cancer, Non-small cell lung cancer, Breast cancer, Hepatocellular carcinoma, Gastric cancer, Central carbon metabolism in cancer, Choline metabolism in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D04024
D04024
|
Lapatinib
| [3] 34 34, 74, 75 |
21 |
EGFR
| [48] EGFR tyrosine kinase inhibitor resistance EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, MAPK signaling pathway, ErbB signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, HIF-1 signaling pathway, FoxO signaling pathway, Phospholipase D signaling pathway, Endocytosis, PI3K-Akt signaling pathway, Focal adhesion, Adherens junction, Gap junction, JAK-STAT signaling pathway, Regulation of actin cytoskeleton, GnRH signaling pathway, Estrogen signaling pathway, Oxytocin signaling pathway, Relaxin signaling pathway, Parathyroid hormone synthesis, secretion and action, Cushing syndrome, Epithelial cell signaling in Helicobacter pylori infection, Shigellosis, Hepatitis C, Human cytomegalovirus infection, Human papillomavirus infection, Coronavirus disease - COVID-19, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Chemical carcinogenesis - receptor activation, Chemical carcinogenesis - reactive oxygen species, Colorectal cancer, Pancreatic cancer, Endometrial cancer, Glioma, Prostate cancer, Melanoma, Bladder cancer, Non-small cell lung cancer, Breast cancer, Hepatocellular carcinoma, Gastric cancer, Central carbon metabolism in cancer, Choline metabolism in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D08108
D08108
|
Lapatinib
| [3] 34 34, 74, 75 |
22 |
ERBB2
| [22] EGFR tyrosine kinase inhibitor resistance EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Platinum drug resistance, MAPK signaling pathway, ErbB signaling pathway, Calcium signaling pathway, HIF-1 signaling pathway, PI3K-Akt signaling pathway, Focal adhesion, Adherens junction, Tight junction, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Pancreatic cancer, Endometrial cancer, Prostate cancer, Bladder cancer, Non-small cell lung cancer, Breast cancer, Gastric cancer, Central carbon metabolism in cancer | D04024
D04024
|
Lapatinib
| [3] 34 34, 74, 75 |
23 |
ERBB2
| [22] EGFR tyrosine kinase inhibitor resistance EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Platinum drug resistance, MAPK signaling pathway, ErbB signaling pathway, Calcium signaling pathway, HIF-1 signaling pathway, PI3K-Akt signaling pathway, Focal adhesion, Adherens junction, Tight junction, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Pancreatic cancer, Endometrial cancer, Prostate cancer, Bladder cancer, Non-small cell lung cancer, Breast cancer, Gastric cancer, Central carbon metabolism in cancer | D08108
D08108
|
Lapatinib
| [3] 34 34, 74, 75 |
24 |
ESR1
| [9] Endocrine resistance Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, Thyroid hormone signaling pathway, Endocrine and other factor-regulated calcium reabsorption, Pathways in cancer, Proteoglycans in cancer, Chemical carcinogenesis - receptor activation, Breast cancer | D00962
D00962
|
Clomifene
| [1] 74 74 |
25 |
ESR1
| [9] Endocrine resistance Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, Thyroid hormone signaling pathway, Endocrine and other factor-regulated calcium reabsorption, Pathways in cancer, Proteoglycans in cancer, Chemical carcinogenesis - receptor activation, Breast cancer | D07726
D07726
|
Clomifene
| [1] 74 74 |
26 |
ESR2
| [7] Endocrine resistance Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, GnRH secretion, Pathways in cancer, Chemical carcinogenesis - receptor activation, Breast cancer | D00962
D00962
|
Clomifene
| [1] 74 74 |
27 |
ESR2
| [7] Endocrine resistance Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, GnRH secretion, Pathways in cancer, Chemical carcinogenesis - receptor activation, Breast cancer | D07726
D07726
|
Clomifene
| [1] 74 74 |
28 |
GHR
| [5] Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Growth hormone synthesis, secretion and action | D02691
D02691
|
Somatotropin
| [23] 2 2, 3, 13, 19, 46, 65, 74, 75, 76, 78, 96, 107, 113, 187, 191, 193, 195, 236, 238, 265, 274, 276, 299 |
29 |
NR3C1
| [1] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D00292
D00292
|
Dexamethasone
| [14] 74 74, 75, 81, 84, 90, 96, 97, 162, 222, 235, 257, 283, 296, 299 |
30 |
NR3C1
| [1] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D00975
D00975
|
Dexamethasone
| [14] 74 74, 75, 81, 84, 90, 96, 97, 162, 222, 235, 257, 283, 296, 299 |
31 |
NR3C1
| [1] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D01510
D01510
|
Dexamethasone
| [14] 74 74, 75, 81, 84, 90, 96, 97, 162, 222, 235, 257, 283, 296, 299 |
32 |
NR3C1
| [1] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D01615
D01615
|
Dexamethasone
| [14] 74 74, 75, 81, 84, 90, 96, 97, 162, 222, 235, 257, 283, 296, 299 |
33 |
NR3C1
| [1] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D01632
D01632
|
Dexamethasone
| [14] 74 74, 75, 81, 84, 90, 96, 97, 162, 222, 235, 257, 283, 296, 299 |
34 |
NR3C1
| [1] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D01948
D01948
|
Dexamethasone
| [14] 74 74, 75, 81, 84, 90, 96, 97, 162, 222, 235, 257, 283, 296, 299 |
35 |
NR3C1
| [1] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D02174
D02174
|
Dexamethasone
| [14] 74 74, 75, 81, 84, 90, 96, 97, 162, 222, 235, 257, 283, 296, 299 |
36 |
NR3C1
| [1] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D02591
D02591
|
Dexamethasone
| [14] 74 74, 75, 81, 84, 90, 96, 97, 162, 222, 235, 257, 283, 296, 299 |
37 |
NR3C1
| [1] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D02592
D02592
|
Dexamethasone
| [14] 74 74, 75, 81, 84, 90, 96, 97, 162, 222, 235, 257, 283, 296, 299 |
38 |
PRL
| [5] Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Prolactin signaling pathway | D00780
D00780
|
Bromocriptine
| [2] 6 6, 74 |
39 |
PRL
| [5] Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Prolactin signaling pathway | D00987
D00987
|
Cabergoline
| [3] 6 6, 74, 75 |
40 |
PRL
| [5] Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Prolactin signaling pathway | D03165
D03165
|
Bromocriptine
| [2] 6 6, 74 |
41 |
SSTR1
| [3] cAMP signaling pathway cAMP signaling pathway, Neuroactive ligand-receptor interaction, Growth hormone synthesis, secretion and action | D10147
D10147
|
Pasireotide
| [3] 67 67, 74, 75 |
42 |
SSTR2
| [4] cAMP signaling pathway cAMP signaling pathway, Neuroactive ligand-receptor interaction, Growth hormone synthesis, secretion and action, Gastric acid secretion | D10147
D10147
|
Pasireotide
| [3] 67 67, 74, 75 |
43 |
SSTR3
| [2] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Growth hormone synthesis, secretion and action | D10147
D10147
|
Pasireotide
| [3] 67 67, 74, 75 |
44 |
SSTR5
| [3] cAMP signaling pathway cAMP signaling pathway, Neuroactive ligand-receptor interaction, Growth hormone synthesis, secretion and action | D10147
D10147
|
Pasireotide
| [3] 67 67, 74, 75 |